CN1259099C - Prepared traditional Chinese drug Liangfu drop pills for treating epigastric pain - Google Patents
Prepared traditional Chinese drug Liangfu drop pills for treating epigastric pain Download PDFInfo
- Publication number
- CN1259099C CN1259099C CN 03124245 CN03124245A CN1259099C CN 1259099 C CN1259099 C CN 1259099C CN 03124245 CN03124245 CN 03124245 CN 03124245 A CN03124245 A CN 03124245A CN 1259099 C CN1259099 C CN 1259099C
- Authority
- CN
- China
- Prior art keywords
- water
- liangfuwan
- extract
- alcohol
- extraction
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- 239000006187 pill Substances 0.000 title claims abstract description 16
- 206010000087 Abdominal pain upper Diseases 0.000 title 1
- 239000003390 Chinese drug Substances 0.000 title 1
- 239000003814 drug Substances 0.000 claims abstract description 41
- 238000002360 preparation method Methods 0.000 claims abstract description 23
- 230000002496 gastric effect Effects 0.000 claims abstract description 18
- 206010000269 abscess Diseases 0.000 claims abstract description 12
- 229940093429 polyethylene glycol 6000 Drugs 0.000 claims abstract description 6
- 239000000284 extract Substances 0.000 claims description 33
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 22
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 20
- 238000005516 engineering process Methods 0.000 claims description 18
- 239000012567 medical material Substances 0.000 claims description 13
- 239000007788 liquid Substances 0.000 claims description 12
- 239000006071 cream Substances 0.000 claims description 11
- 238000001035 drying Methods 0.000 claims description 10
- 238000003810 ethyl acetate extraction Methods 0.000 claims description 10
- 239000000758 substrate Substances 0.000 claims description 8
- 239000002202 Polyethylene glycol Substances 0.000 claims description 5
- 238000002481 ethanol extraction Methods 0.000 claims description 5
- 230000004927 fusion Effects 0.000 claims description 5
- 238000009413 insulation Methods 0.000 claims description 5
- 229940057995 liquid paraffin Drugs 0.000 claims description 5
- 239000012188 paraffin wax Substances 0.000 claims description 5
- 229920001223 polyethylene glycol Polymers 0.000 claims description 5
- 238000003809 water extraction Methods 0.000 claims description 5
- 238000000605 extraction Methods 0.000 claims description 4
- 229940079593 drug Drugs 0.000 abstract description 17
- 239000000463 material Substances 0.000 abstract description 9
- 230000000694 effects Effects 0.000 abstract description 7
- 239000000428 dust Substances 0.000 abstract description 4
- 238000009833 condensation Methods 0.000 abstract description 2
- 230000005494 condensation Effects 0.000 abstract description 2
- 230000005496 eutectics Effects 0.000 abstract description 2
- 238000003908 quality control method Methods 0.000 abstract description 2
- 244000150195 Cyperus longus Species 0.000 abstract 2
- 230000002349 favourable effect Effects 0.000 abstract 2
- 244000062241 Kaempferia galanga Species 0.000 abstract 1
- 235000013421 Kaempferia galanga Nutrition 0.000 abstract 1
- 239000010419 fine particle Substances 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
- 239000000126 substance Substances 0.000 abstract 1
- 241001465754 Metazoa Species 0.000 description 14
- SQFSKOYWJBQGKQ-UHFFFAOYSA-N kaempferide Chemical group C1=CC(OC)=CC=C1C1=C(O)C(=O)C2=C(O)C=C(O)C=C2O1 SQFSKOYWJBQGKQ-UHFFFAOYSA-N 0.000 description 12
- 238000000034 method Methods 0.000 description 12
- 239000002552 dosage form Substances 0.000 description 11
- 241000699670 Mus sp. Species 0.000 description 7
- 230000037396 body weight Effects 0.000 description 7
- 238000002474 experimental method Methods 0.000 description 7
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 6
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical group OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 6
- 239000000243 solution Substances 0.000 description 6
- 210000002784 stomach Anatomy 0.000 description 6
- 238000004090 dissolution Methods 0.000 description 5
- 230000036407 pain Effects 0.000 description 5
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 4
- 230000000202 analgesic effect Effects 0.000 description 4
- 239000003153 chemical reaction reagent Substances 0.000 description 4
- 239000004615 ingredient Substances 0.000 description 4
- 238000007689 inspection Methods 0.000 description 4
- 230000000087 stabilizing effect Effects 0.000 description 4
- 241000700159 Rattus Species 0.000 description 3
- 208000005392 Spasm Diseases 0.000 description 3
- OIPILFWXSMYKGL-UHFFFAOYSA-N acetylcholine Chemical compound CC(=O)OCC[N+](C)(C)C OIPILFWXSMYKGL-UHFFFAOYSA-N 0.000 description 3
- JUGOREOARAHOCO-UHFFFAOYSA-M acetylcholine chloride Chemical compound [Cl-].CC(=O)OCC[N+](C)(C)C JUGOREOARAHOCO-UHFFFAOYSA-M 0.000 description 3
- 238000001914 filtration Methods 0.000 description 3
- 238000002347 injection Methods 0.000 description 3
- 239000007924 injection Substances 0.000 description 3
- 239000002932 luster Substances 0.000 description 3
- 238000011020 pilot scale process Methods 0.000 description 3
- 238000010992 reflux Methods 0.000 description 3
- 239000000725 suspension Substances 0.000 description 3
- 238000012449 Kunming mouse Methods 0.000 description 2
- 241000700157 Rattus norvegicus Species 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- 238000010521 absorption reaction Methods 0.000 description 2
- 229960004373 acetylcholine Drugs 0.000 description 2
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 2
- 238000010171 animal model Methods 0.000 description 2
- 230000009286 beneficial effect Effects 0.000 description 2
- 230000000857 drug effect Effects 0.000 description 2
- 238000001727 in vivo Methods 0.000 description 2
- 239000004033 plastic Substances 0.000 description 2
- 229920003023 plastic Polymers 0.000 description 2
- 239000013641 positive control Substances 0.000 description 2
- 239000000843 powder Substances 0.000 description 2
- 239000013558 reference substance Substances 0.000 description 2
- 238000012109 statistical procedure Methods 0.000 description 2
- 206010002091 Anaesthesia Diseases 0.000 description 1
- 229920002134 Carboxymethyl cellulose Polymers 0.000 description 1
- JOYRKODLDBILNP-UHFFFAOYSA-N Ethyl urethane Chemical compound CCOC(N)=O JOYRKODLDBILNP-UHFFFAOYSA-N 0.000 description 1
- 206010068676 Pneumoretroperitoneum Diseases 0.000 description 1
- 208000005727 Retropneumoperitoneum Diseases 0.000 description 1
- GAMYVSCDDLXAQW-AOIWZFSPSA-N Thermopsosid Natural products O(C)c1c(O)ccc(C=2Oc3c(c(O)cc(O[C@H]4[C@H](O)[C@@H](O)[C@H](O)[C@H](CO)O4)c3)C(=O)C=2)c1 GAMYVSCDDLXAQW-AOIWZFSPSA-N 0.000 description 1
- 210000000683 abdominal cavity Anatomy 0.000 description 1
- 230000003187 abdominal effect Effects 0.000 description 1
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- 230000037005 anaesthesia Effects 0.000 description 1
- 235000010948 carboxy methyl cellulose Nutrition 0.000 description 1
- 229920003123 carboxymethyl cellulose sodium Polymers 0.000 description 1
- 229940063834 carboxymethylcellulose sodium Drugs 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 239000000812 cholinergic antagonist Substances 0.000 description 1
- 238000002425 crystallisation Methods 0.000 description 1
- 230000008025 crystallization Effects 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 230000002183 duodenal effect Effects 0.000 description 1
- 210000001198 duodenum Anatomy 0.000 description 1
- 229930003944 flavone Natural products 0.000 description 1
- -1 flavone compound Chemical class 0.000 description 1
- 235000011949 flavones Nutrition 0.000 description 1
- 238000003304 gavage Methods 0.000 description 1
- 238000004128 high performance liquid chromatography Methods 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 238000002844 melting Methods 0.000 description 1
- 230000008018 melting Effects 0.000 description 1
- 239000011859 microparticle Substances 0.000 description 1
- 238000000465 moulding Methods 0.000 description 1
- 230000003285 pharmacodynamic effect Effects 0.000 description 1
- 238000003825 pressing Methods 0.000 description 1
- 238000007670 refining Methods 0.000 description 1
- 239000007962 solid dispersion Substances 0.000 description 1
- 230000002048 spasmolytic effect Effects 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- 239000000052 vinegar Substances 0.000 description 1
- 235000021419 vinegar Nutrition 0.000 description 1
- VHBFFQKBGNRLFZ-UHFFFAOYSA-N vitamin p Natural products O1C2=CC=CC=C2C(=O)C=C1C1=CC=CC=C1 VHBFFQKBGNRLFZ-UHFFFAOYSA-N 0.000 description 1
Landscapes
- Medicines Containing Plant Substances (AREA)
- Medicinal Preparation (AREA)
Abstract
The present invention discloses a Chinese patent medicine named drop pill with galangal and nutgrass galingale rhizome, which is used for curing gastric abscess. The medicinal composition is prepared from polyethylene glycol 6000 and extractives of glaangal and nutgrass galingale rhizome, wherein the polyethylene glycol 6000 is used as base material; the extractives are used as active components; the weight part ratio of the active components to the base material is from 1:2.5 to 1:3.5. the present invention has the advantages that: 1) the taking dose is small and only 10 to 20 pills are taken at each time, which is convenient for patients particularly senile patients to accept and to take; 2) the dissolving speed is quick, which is favorable for human bodies to absorb, and the effect taking time of the medicines is brought forward; 3) the bioavailability is high; the medicinal materials are refined; the effective components are concentrated; after the medicines and the base material are together melted, the medicines are evenly dispersed in the base material, which can rapidly perform curative effect when the medicines form a eutectic solution through condensation; 4) the quality is stable; a quality control standard is established, so the single dose is exact; the fine particles of medicines are embeded in the substance of the base material, and no apertuer gap exits, so air can not diffuse in; the preparation processes have simple and convenient opration and no dust pollution, and is favorable to labour protection.
Description
Technical field
The present invention relates to a kind of Chinese patent medicine liangfuwan and preparation technology thereof who treats gastric abscess, belong to field of traditional Chinese, more precisely improvement dosage form and the preparation technology thereof on the basis of former dosage form Liang Fu Wan.
Background technology
Liang Fu Wan is the ancient dosage form watered pill, is used for the treatment of gastric abscess, has significant curative effect through the proof of clinical practice for many years, but owing to be subjected to the limitation of dosage form and dose, and can not satisfy vast gastric abscess patient demand far away.
At first, the molten diffusing time of Liang Fu Wan is grown (30 minutes), causes oral absorption slower, has reduced bioavailability, is unfavorable for the drug effect performance; Secondly, taking dose is bigger, and each about 47～94 balls of dose (being equivalent to crude drug amount 3～6 grams) cause the inconvenience of taking medicine to patient especially old people; Moreover Liang Fu Wan medicine instability is placed the change that active substance content promptly took place in a year, is unfavorable for storage; And the preparation technology of Liang Fu Wan is ground into direct general ball molding behind the powder with the prescription medical material, because at present no quality standard is controlled, manufactured goods all have much room for improvement at aspects such as dissolubility, dissolution rate, bioavailability and stability; And have the dust pollution phenomenon in the production process, be unfavorable for labor protection.
Therefore, be badly in need of a kind of novel form that can overcome the Liang Fu Wan of above shortcoming of exploitation.
Summary of the invention
The purpose of this invention is to provide that a kind of taking dose is little, dissolution velocity is fast, bioavailability is high, the Chinese patent medicine liangfuwan of stay-in-grade treatment gastric abscess.
Another object of the present invention provides a kind of preparation technology of this liangfuwan of easy and simple to handle, quality controllable, no dust pollution.
A kind of Chinese patent medicine liangfuwan for the treatment of gastric abscess, it is by making as the polyethylene glycol 6000 of substrate with as the Rhizoma Alpiniae Officinarum of active component and the extract of Rhizoma Cyperi (processing).Described " processing " means the processed with vinegar of one of Chinese medicine processing, sees under the pharmacopeia appendix II D item.With ratio of weight and number is that 1: 1 Rhizoma Alpiniae Officinarum and Rhizoma Cyperi (processing) extracted with the second alcohol and water, is condensed into extractum respectively, and reuse ethyl acetate extraction, extract are concentrated into the dried dried cream of extract that becomes, and are active component.
The ratio of weight and number of described active component and substrate is 1: 2.5～1: 3.5.
Described active component is to be made through extracting according to 1: 1 ratio of weight and number by Rhizoma Alpiniae Officinarum and Rhizoma Cyperi (processing).
Describedly be extracted as alcohol extraction or water is carried or water alcohol mixes and carries.
A kind of preparation technology who treats the Chinese patent medicine liangfuwan of gastric abscess comprises the steps:
1) medical material is handled: 500 gram Rhizoma Alpiniae Officinarum and 500 gram Rhizoma Cyperis (processing) are extracted with the second alcohol and water, be condensed into extractum respectively, reuse ethyl acetate extraction, extract are concentrated into the dried dried cream of extract that becomes;
2) medicinal liquid preparation: taking polyethylene glycol 6000 is put in the container, is heated to 70～80 ℃ in water-bath, treat whole fusions after, be that 1: 2.5～3.5 ratio adds the dried cream of extract according to the dried cream of extract and Polyethylene Glycol ratio of weight and number, be stirred to dissolving, even;
3) drip system: the medicinal liquid for preparing is transferred in the reservoir, and airtight and insulation is at 70 ℃, and regulator solution titer valve splashes in 5～10 ℃ the liquid paraffin:
4) drying: with the drop pill drop that forms to the greatest extent and the erasing liquor paraffin body, drying, promptly.
Extract with the second alcohol and water in the described medical material treatment step and be meant respectively and respectively extract 2 times with the second alcohol and water.Concentration of alcohol in the described medical material treatment step is 85～95%, V/V.
Be meant usefulness ethyl acetate extraction 4 times with ethyl acetate extraction in the described medical material treatment step, each consumption is 1000ml.
The described extraction with ethanol is meant each usefulness 6000～8000ml ethanol extraction 1 hour.
Described water extracts and is meant each usefulness 8000～10000ml water extraction half an hour.
Advantage of the present invention is: liangfuwan extracts through refining, and the solid dispersion technology of application of advanced is prepared from, and it has not only overcome the deficiency of original dosage form, brings following significant advantage simultaneously:
1) taking dose is little: every clothes dosage is 10～20 balls only, take 1/4 of dose for former dosage form, are equivalent to crude drug 3～6 gram equally, be convenient to the patient especially the gerontal patient accept and take.
2) dissolution velocity is fast: dissolve scattered time limit has been accelerated medicine dissolution velocity in vivo for being 6 minutes only, is beneficial to absorption of human body and has shifted to an earlier date the drug effect time.
3) bioavailability height: medical material is made with extra care, and effective ingredient has obtained concentrating; After medicine and the substrate congruent melting medicine is dispersed in the substrate, when eutectic solution was formed in condensation, medicine and substrate generated two kinds of superfine crystallizations simultaneously, helped absorbing, and brought into play curative effect rapidly, improved bioavailability.
4) steady quality: formulated quality control standard, single dose is accurate; Drug microparticles is embedded in the substrate entity, the imporosity, and air can not spread into, thereby has increased stability of drug.
5) easy and simple to handle, the no dust pollution of preparation process is beneficial to labor protection.
In sum, the present invention has good prospects for application at the aspects such as dissolubility, dissolution rate and bioavailability that improve medicine, is treatment gastric abscess disease, realizes the forward position pharmaceutical dosage form that the modernization of Chinese medicine develops.
The specific embodiment
The preparation of embodiment 1, liangfuwan
1, prescription: Rhizoma Alpiniae Officinarum 500g, Rhizoma Cyperi (processing) 500g
2, method for making:
1) medical material is handled: with Rhizoma Alpiniae Officinarum and Rhizoma Cyperi (processing) according to recipe quantity with each reflux, extract, of 95% (V/V) second alcohol and water 2 times, each 6000ml extracted 1 hour during with 95% (V/V) ethanol extraction, each 8000ml extracts half an hour during with water extraction, be condensed into extractum respectively, relative density is for being respectively 1.25 and 1.10; Add 1000ml water, make extractum become suspension, reuse ethyl acetate extraction 4 times, each 1000ml, extract are concentrated into the dried dried cream of extract that becomes after filtering and merging, and paste-forming rate is 3.4%.
2) medicinal liquid preparation: get 85 gram polyethylene glycol 6000s and put in the container, in water-bath, be heated to 70 ℃, treat whole fusions after, add extract 34 grams (by 1: 2.5), be stirred to dissolving, even;
3) drip system: the medicinal liquid for preparing is transferred in the reservoir, and airtight and insulation is at 70 ℃, and regulator solution titer valve splashes in 5 ℃ the liquid paraffin;
4) drying: with the drop pill drop that forms to the greatest extent and the erasing liquor paraffin body, drying, promptly.
This drop pill specification is every ball 45mg.On inspection, the drop pill outward appearance rounding of making, big or small homogeneous, color and luster unanimity; Weight differential complies with relevant regulations.Instructions of taking: oral, usual amounts is one time 10～20 ball, 3 times on the one.
This technology shows through pilot scale research, and prescription is formed rationally, process stabilizing, controlled, easy row.
The preparation of embodiment 2, liangfuwan
1, prescription: Rhizoma Alpiniae Officinarum 500g, Rhizoma Cyperi (processing) 500g
2, method for making:
1) medical material is handled: with Rhizoma Alpiniae Officinarum and Rhizoma Cyperi (processing) according to recipe quantity with each reflux, extract, of 85% (V/V) second alcohol and water 2 times, each 8000ml extracted 1 hour during with 85% (V/V) ethanol extraction, each 10000ml extracts half an hour during with water extraction, be condensed into extractum respectively, relative density is for being respectively 1.35 and 1.15; Add 1000ml water, make extractum become suspension, reuse ethyl acetate extraction 4 times, each 1000ml, extract are concentrated into the dried dried cream of extract that becomes after filtering and merging, and paste-forming rate is 3.8%.
2) medicinal liquid preparation: get 133 gram polyethylene glycol 6000s and put in the container, in water-bath, be heated to 80 ℃, treat whole fusions after, add dried cream 38 grams of extract (by 1: 3.5), be stirred to dissolving, even;
3) drip system: the medicinal liquid for preparing is transferred in the reservoir, and airtight and insulation is at 70 ℃, and regulator solution titer valve splashes in 10 ℃ the liquid paraffin;
4) drying: with the drop pill drop that forms to the greatest extent and the erasing liquor paraffin body, drying, promptly.
This drop pill specification is every ball 45mg.On inspection, the drop pill outward appearance rounding of making, big or small homogeneous, color and luster unanimity; Weight differential complies with relevant regulations.Instructions of taking: oral, usual amounts is one time 10～20 ball, 3 times on the one.
This technology shows through pilot scale research, and prescription is formed rationally, process stabilizing, controlled, easy row.
The preparation of embodiment 3, liangfuwan
1, prescription: Rhizoma Alpiniae Officinarum 500g, Rhizoma Cyperi (processing) 500g
2, method for making:
1) medical material is handled: with Rhizoma Alpiniae Officinarum and Rhizoma Cyperi (processing) according to recipe quantity with each reflux, extract, of 90% (V/V) second alcohol and water 2 times, each 7000ml extracted 1 hour during with 90% (V/V) ethanol extraction, each 9000ml extracts half an hour during with water extraction, be condensed into extractum respectively, relative density is for being respectively 1.30 and 1.12; Add 1000ml water, make extractum become suspension, reuse ethyl acetate extraction 4 times, each 1000ml, extract are concentrated into the dried dried cream of extract that becomes after filtering and merging, and paste-forming rate is 3.5%.
2) medicinal liquid preparation: get 105 gram polyethylene glycol 6000s and put in the container, in water-bath, be heated to 75 ℃, treat whole fusions after, add extract 35 grams (by 1: 3), be stirred to dissolving, even;
3) drip system: the medicinal liquid for preparing is transferred in the reservoir, and airtight and insulation is at 70 ℃, and regulator solution titer valve splashes in 8 ℃ the liquid paraffin;
4) drying: with the drop pill drop that forms to the greatest extent and the erasing liquor paraffin body, drying, promptly.
This drop pill specification is every ball 45mg.On inspection, the drop pill outward appearance rounding of making, big or small homogeneous, color and luster unanimity; Weight differential complies with relevant regulations.Instructions of taking: oral, usual amounts is one time 10～20 ball, 3 times on the one.
This technology shows through pilot scale research, and prescription is formed rationally, process stabilizing, controlled, easy row.
Embodiment 4, experiment disintegration
1, material: liangfuwan lot number 20020918 (preparation of liangfuwan seminar)
Liang Fu Wan lot number 20000214 (Zhenjiang pharmaceutical factory of traditional Chinese medicine product)
2, method: according to Chinese Pharmacopoeia version appendix in 2000 XII A item following disintegration of inspection method, check its disintegration, use instrument to be disintegration instrument CHP-II type (Tianjin electronic machine two factories)
3, result: former Liang Fu Wan disintegration is 30 minutes, and liangfuwan is 6 minutes.
4, conclusion: liangfuwan instrument disintegration is 6 minutes, is 1/5 of former Liang Fu Wan disintegration, shows that liangfuwan is molten rapidly in vivo to loose, and onset time is short, can bring into play curative effect rapidly.
Embodiment 5, stability experiment
1, material: instrument is high performance liquid chromatograph HP-110, disintegration instrument CHP-II type (Tianjin electronic machine two factories)
Chromatographic column is YWG-C1H 4.6mm * 250mm (the three-dimensional chromatographic apparatus in a Tianjin factory)
Reagent is methanol, phosphoric acid, and water etc. are analytical pure (Tianjin reagent two factories) all
Reference substance is kaempferide (purchasing in Nat'l Pharmaceutical ﹠ Biological Products Control Institute)
2, method: according to the contained effective ingredient of liangfuwan is flavone compound, and kaempferide is one of effective ingredient wherein,, formulates with kaempferide as component target control technology stable in order to make process stabilizing.Its method is to adopt high performance liquid chromatography, is reference substance with the kaempferide, and methanol: phosphoric acid: water is mobile phase, is the 368nm place detecting wavelength, measures kaempferide content in the liangfuwan.And adopt disintegration tester to measure dissolve scattered time limit.
3, result:
Liang Fu Wan and liangfuwan stability experiment result
4, conclusion: above-mentioned experiment shows: at the aspects such as content of outward appearance, dissolve scattered time limit and effective ingredient kaempferide, liangfuwan is all stable than Liang Fu Wan.
Embodiment 6, effect experiment
1, material
1) be subjected to the reagent thing:
Liangfuwan: brown drop pill, every gram contain crude drug 7.99 grams (liangfuwan seminar provides)
Liang Fu Wan: positive control drug, lot number 20000214 (Zhenjiang pharmaceutical factory of traditional Chinese medicine product)
Acecoline: white powder, lot number 20000420 (Shanghai reagent three factories product)
2) animal:
Kunming mouse, male and female half and half, body weight 18-22 gram; Wistar rat male and female half and half, body weight restrains at 250-300.Above animal breeds by the court animal housing, the Laboratory Animal Facility quality certification " accurate No. 013 of the real moving facility in Tianjin ", and committee issues by the Tianjin management of laboratory animal, meets primary standard. normally raise after 3 days for usefulness.
3) instrument: pressure transducer (YP100) .056 monitor (HIT's product)
2, method:
1) to the analgesic activity of mice:
Kunming mouse, male and female half and half, body weight 18～22 gram. the acetum 0.2ml/g body weight of the equal lumbar injection 0.6% of each mice the previous day, that writes down each mice in 15 minutes turns round the body number of times.Got in second day and turn round 92 of the mice of body number of times within 20～45 times in 15 minutes, knob body number of times is divided into 6 groups at random, 10 every group.The administration group is irritated stomach liangfuwan and positive drug Liang Fu Wan, the carboxymethylcellulose sodium solution of blank oral administration gavage 0.5% acecoline, one day twice, accumulated dose is 12.0g crude drug/Kg, give the acetic acid 0.2ml/20g body weight of wanting pneumoretroperitoneum injection 0.6% in a hour for the second time, write down respectively organize mice in 15 minutes turn round the body number of times, experimental result is carried out statistical procedures with the t check.
2) diastole to rat stomach influences:
48 of Wistar rats, male and female half and half, body weight 250～300 grams, fasting is 24 hours before the experiment, freely drinks water, be divided into 6 groups at random by body weight, every group 8, the administration group is respectively to liangfuwan and positive control drug Liang Fu Wan, and dosage is 6g crude drug/Kg, the blank group gives 0.5%CMC, urethane anesthesia (1.2g/Kg, ip), the abdominal part median incision, expose the abdominal cavity, insert a thin plastic pipe to gastral cavity through the duodenum otch, ligation is fixed, and cleans gastral cavity repeatedly with normal saline (37 ℃) and ends to flowing out clear liquid. inject the normal saline of 37 ℃ of 2ml again to gastral cavity from plastic tube, intubate is connected in pressure transducer, stablized duodenal administration, 1 hour lumbar injection behind the medicine 30 minutes, acecoline (3mg/Kg) is pressed variation with autographic apparatus record gastric. and experimental result is carried out statistical procedures with the t check.
3, result:
1) to the analgesic activity of mice: see Table 1
Table 1 liangfuwan is to the analgesic activity of mice
| Group | Dosage (the g crude drug/Kg) | Animal (only) | Turn round body number of times ± sd (inferior/15 minute) |
| Blank group | -- | 10 | 30.6±8.8 |
| Liang Fu Wan | 12 | 10 | 13.1±9.9** |
| Liangfuwan | 12 | 10 | 13.6±16.0** |
Annotate: * * compares P＜0.01 with the blank group
The result shows, after blank group causes pain model with acetic acid, in 15 minutes of record, the animal that is caused by pain is turned round the number of times average out to 30.6 of body, and the statistical standard difference is 8.8 times, after animal gives the former dosage form treatment of Liang Fu Wan, the animal that is caused by pain is turned round the number of times on average remaining 13.1 times of body, and after animal gave the treatment of novel form liangfuwan, the animal that is caused by pain was turned round the number of times on average remaining 13.6 times of body, it is about 60% to illustrate that medicine reduces pain reaction, novel form and former dosage form basically identical.
2) diastole to rat stomach influences: see Table 2
Table 2: the influence that liangfuwan is pressed the anesthetized rat gastric
| Behind the medicine | Dosage (the g crude drug/Kg) | Animal (only) | Before the medicine | After the gastric pressing | Behind the Ach | ΔP |
| Blank | 8 | 8 | 5.59±2.78 | 6.03±3.09 | 12.68±3.51 | 6.65±2.95 |
| Liang Fu Wan | 6 | 8 | 5.86±1.61 | 4.81±1.41 | 8.20±3.54* | 3.39±3.19 |
| Liangfuwan | 6 | 8 | 5.46±2.31 | 5.71±2.52 | 7.69±2.72** | 1.98±1.63 |
Annotate: * compares P＜0.05 with blank, * * compares P＜0.014 with the blank group
The result shows, after blank group causes experimental stomach spasm with acetylcholine (ACH), high nearly one times of gastric voltage rise, after animal gives the former dosage form treatment of Liang Fu Wan, it is high about 50% to have alleviated gastric voltage rise that stomach spasm causes, after animal gives the treatment of novel form liangfuwan, has alleviated the gastric voltage rise high about 70% that stomach spasm causes, illustrate that medicine has spasmolysis, novel form be better than former dosage form.
4, conclusion: pharmacodynamic experiment shows that liangfuwan has spasmolytic, analgesic activity, and the convection potential gastric abscess has significant curative effect.
Claims (10)
1, a kind of Chinese patent medicine liangfuwan for the treatment of gastric abscess, it is by making as the polyethylene glycol 6000 of substrate with as the Rhizoma Alpiniae Officinarum of active component and the extract of prepared RHIZOMA CYPERI.
2, liangfuwan according to claim 1 is characterized in that: the ratio of weight and number of described active component and substrate is 1: 2.5～1: 3.5.
3, liangfuwan according to claim 1 is characterized in that: described active component is to be made through extracting according to 1: 1 ratio of weight and number by Rhizoma Alpiniae Officinarum and prepared RHIZOMA CYPERI.
4, liangfuwan according to claim 3 is characterized in that: describedly be extracted as alcohol extraction or water is carried or water alcohol mixes and carries.
5, a kind of preparation technology who treats the Chinese patent medicine liangfuwan of gastric abscess comprises the steps:
1) medical material is handled: 500 gram Rhizoma Alpiniae Officinarum and 500 gram prepared RHIZOMA CYPERIs are extracted with the second alcohol and water, be condensed into extractum respectively, reuse ethyl acetate extraction, extract are concentrated into the dried dried cream of extract that becomes;
2) medicinal liquid preparation: taking polyethylene glycol 6000 is put in the container, is heated to 70～80 ℃ in water-bath, treat whole fusions after, be that 1: 2.5～3.5 ratio adds the dried cream of extract according to the dried cream of extract and Polyethylene Glycol ratio of weight and number, be stirred to dissolving, even;
3) drip system: the medicinal liquid for preparing is transferred in the reservoir, and airtight and insulation is at 70 ℃, and regulator solution titer valve splashes in 5～10 ℃ the liquid paraffin;
4) drying: with the drop pill drop that forms to the greatest extent and the erasing liquor paraffin body, drying, promptly.
6, preparation technology according to claim 5 is characterized in that: the concentration of alcohol in the described medical material treatment step is 85～95%, V/V.
7, preparation technology according to claim 5 is characterized in that: extract with the second alcohol and water in the described medical material treatment step and be meant with respectively extracting 2 times with the second alcohol and water respectively.
8, preparation technology according to claim 5 is characterized in that: be meant usefulness ethyl acetate extraction 4 times with ethyl acetate extraction in the described medical material treatment step, each consumption is 1000ml.
9, preparation technology according to claim 7 is characterized in that: the described extraction with ethanol is meant each usefulness 6000～8000ml ethanol extraction 1 hour.
10, preparation technology according to claim 7 is characterized in that: described water extracts and is meant each usefulness 8000～10000ml water extraction half an hour.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN 03124245 CN1259099C (en) | 2003-04-30 | 2003-04-30 | Prepared traditional Chinese drug Liangfu drop pills for treating epigastric pain |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN 03124245 CN1259099C (en) | 2003-04-30 | 2003-04-30 | Prepared traditional Chinese drug Liangfu drop pills for treating epigastric pain |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN1541669A CN1541669A (en) | 2004-11-03 |
| CN1259099C true CN1259099C (en) | 2006-06-14 |
Family
ID=34321608
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN 03124245 Expired - Fee Related CN1259099C (en) | 2003-04-30 | 2003-04-30 | Prepared traditional Chinese drug Liangfu drop pills for treating epigastric pain |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN1259099C (en) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1310029C (en) * | 2005-01-14 | 2007-04-11 | 贵州黄果树立爽药业有限公司 | Method for preparing liangfuwan and method for controlling quality |
| CN101926949B (en) * | 2009-06-25 | 2012-04-18 | 天津太平洋制药有限公司 | Preparation process of galangal and rhizoma cyperi liquid capsule |
| CN102552781A (en) * | 2010-12-27 | 2012-07-11 | 天津药物研究院 | Chinese medicinal preparation galanga-nutgrass galingale rhizome tablet for treating epigastric pain and preparation method thereof |
| CN105056058A (en) * | 2015-07-16 | 2015-11-18 | 王乾林 | Traditional Chinese medicine pharmaceutical for treating stomachache with cold and qi stagnation |
-
2003
- 2003-04-30 CN CN 03124245 patent/CN1259099C/en not_active Expired - Fee Related
Also Published As
| Publication number | Publication date |
|---|---|
| CN1541669A (en) | 2004-11-03 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN101057925A (en) | Preparation technology for 'jieguqili' capsule and its quality control method | |
| CN1259099C (en) | Prepared traditional Chinese drug Liangfu drop pills for treating epigastric pain | |
| CN1301098C (en) | Hairy holly root drip pill and its preparation method | |
| CN100341487C (en) | 'Shuanghuang' antiphlogistic drop pill in use relieving inflammation and preparation method | |
| CN1316961C (en) | Grosvenor's momordica fruit drip pill an dits preparation method | |
| CN1686342A (en) | Herminium drip pill and its preparation method | |
| CN1660364A (en) | 'Lianzhi' anti inflammation drop pill in use for clearing away heat and toxic material and preparation method | |
| CN1301100C (en) | Nauclea officinalis drip pill and its preparation method | |
| CN1301101C (en) | Oral drip pill used for cough suppressing phlegm transforming and its preparation method | |
| CN1686452A (en) | Two kinds of oral drip pills for treating tracheitis and its preparation method | |
| CN1292738C (en) | Ginseng-pilose antler dripping pill for tonifying heart and kidney and its preparing method | |
| CN1660316A (en) | Drop pills preparation in use for treating bronchitis and preparation method | |
| CN1307981C (en) | Xuening dripping pill having hemostatic function and its preparing method | |
| CN1698785A (en) | Dripping pills of abastard speedwell and its preparation process | |
| CN1682816A (en) | Xiaoaiping dripping pill for treating various cancers and its preparing method | |
| CN1709413A (en) | Golden gallbladder-normalizing dropping pill for relaxing-liver and normalizing gallbladder, and its preparing method | |
| CN1709414A (en) | Compound liver-benefiting dropping pill for treating hepatitis and its preparing method | |
| CN1686454A (en) | Xiaoke drip pill used for suppressing cough and transforming phlegm and its preparation method | |
| CN1698633A (en) | Glycyrrhizin drop pills and preparation method thereof | |
| CN1301107C (en) | Xiyanping drop pills of possessing function of clearing away heat and toxic materia and preparation method | |
| CN1284530C (en) | Compound tornado drop pills | |
| CN1698797A (en) | Blood pressure lowering dripping pills with chryanthemum flower and pearl and its preparation process | |
| CN1682822A (en) | Bupleurum root and asarum herb dripping pill and its preparing method | |
| CN1660317A (en) | Powerful drop pills of loquat in use for relieving cough and eliminating sputum and preparing method | |
| CN1720964A (en) | Stomachache easing dripping pills with celandine as raw materials and its preparation process |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| ASS | Succession or assignment of patent right |
Owner name: TIANJIN TAIPU PHARMACEUTICAL INTELLECTUAL PROPERTY Free format text: FORMER OWNER: TIANJIN INSTITUTE OF PHARMACEUTICAL RESEARCH Effective date: 20130130 |
|
| C41 | Transfer of patent application or patent right or utility model | ||
| TR01 | Transfer of patent right |
Effective date of registration: 20130130 Address after: 300193 Tianjin City, Nankai District Anshan West Road No. 308 Patentee after: Tianjin Taipu Pharmaceutical Intellectual Property Flow Reserve Center Co, Ltd. Address before: 300193 Tianjin City, Nankai District Anshan West Road No. 308 Patentee before: Tianjin Institute of Pharmaceutical Research |
|
| ASS | Succession or assignment of patent right |
Owner name: TIANJIN INSTITUTE OF PHARMACEUTICAL RESEARCH Free format text: FORMER OWNER: TIANJIN TAIPU PHARMACEUTICAL INTELLECTUAL PROPERTY TRANSFER RESERVE CENTER CO., LTD. Effective date: 20140430 |
|
| C41 | Transfer of patent application or patent right or utility model | ||
| TR01 | Transfer of patent right |
Effective date of registration: 20140430 Address after: 300193 Tianjin City, Nankai District Anshan West Road No. 308 Patentee after: Tianjin Institute of Pharmaceutical Research Address before: 300193 Tianjin City, Nankai District Anshan West Road No. 308 Patentee before: Tianjin Taipu Pharmaceutical Intellectual Property Flow Reserve Center Co, Ltd. |
|
| CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20060614 Termination date: 20170430 |
|
| CF01 | Termination of patent right due to non-payment of annual fee |